Study of LM-108 with chemo for advanced pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called LM-108 combined with chemotherapy for people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if it's safe and may help shrink tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic pancreatic cancer that cannot be removed by surgery and you have not had any prior treatment for this stage.
- You are generally well enough to carry out daily activities (ECOG score 0-1).
- You have at least one tumor that can be measured on scans.
- You agree to use effective birth control if you are able to have children, and women must have a negative pregnancy test before starting.
- You have not had certain other cancer treatments or conditions like unstable brain metastases, active autoimmune disease, or recent major surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment for people with stage 4 pancreatic cancer who haven't yet had any treatment for advanced disease. The goal is to see if the new treatment can help shrink or control the cancer.
This trial tests AK104 (an antibody medicine) given with standard chemotherapy as the first treatment for advanced pancreatic ductal cancer. It aims to see whether this combination works better and is safe for people with cancer that has spread or is advanced.
This trial tests a new treatment called QLS31905 plus chemotherapy against a placebo plus chemotherapy for people with advanced pancreatic cancer that hasn't been treated yet. It aims to see if the new combination works better.
This trial tests a new drug (TQB2916) combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for metastatic pancreatic cancer. It aims to see if the combination works better than chemo alone.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
This trial tests a new medicine (FG-M108) combined with chemotherapy for pancreatic cancer that is advanced or has spread. The medicine targets a protein found on some pancreatic cancer cells, and the goal is to see if it helps shrink tumors or slow the cancer more than chemotherapy alone.
Hear when a new Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.